News | June 07, 2011

Solution for Expanding Clinical Utilization in Nuclear Cardiology

June 7, 2011 – At the Society of Nulear Medicine (SNM) 2011 meeting this week, Siemens Healthcare demonstrated how users of the Symbia S and Symbia T series, single-photon emission computed tomography (SPECT) and SPECT•CT systems, respectively, are taking advantage of IQ•SPECT, to dramatically reduce the length of imaging protocols. A field-upgradeable combination of hardware and software, IQ•SPECT is helping nuclear cardiologists cut the cardiac imaging protocol from approximately 20 minutes to less than five minutes. These shortened exams enable a sustainable approach to nuclear cardiology that potentially enables decreased radiation dose to patients, assists to make the procedure more tolerable for the elderly, provides high quality diagnostic information, and allows users to better utilize an imaging resource that is hampered by limited availability of the key radiotracer.

“There is a significant difference between a four-minute SPECT scan with IQ•SPECT and a conventional 20-minute SPECT because many older patients cannot tolerate a longer scan; in our practice IQ•SPECT provides the opportunity to obtain quality SPECT imaging information in cases where it would not have been possible to even attempt imaging,” said James R. Corbett, M.D., director, cardiovascular nuclear medicine, professor, departments of internal medicine and radiology, University Hospital, University of Michigan Health System, Ann Arbor.

In recognition of its market-differentiating features, Siemens recently received the Product Differentiation Excellence Award, Nuclear Cardiology, North America, 2011, from industry analyst group Frost & Sullivan.

“Despite the benefits to clinical decision making conferred by the modality, the cardiac SPECT market has been faced with challenging circumstances that have led to a significant shift in the traditional provider setting,” said Sangeetha Prabakar, industry analyst, Frost & Sullivan. “With IQ•SPECT, Siemens has delivered a solution that addresses the cost sensibilities engendered by decreased reimbursement and the relative scarcity of the radiotracer.”

IQ•SPECT brings enhanced value to patients, medical facilities, and cardiologists and is an ideal fit for hospital-based cardiology imaging needs. It has been shown to reduce radiotracer doses by up to 50 percent, thus translating into lower amounts of radiation for the patient, and potential increased cost savings and access to radiotracer supply for the medical facility.

IQ•SPECT utilizes SmartZoom collimators, which focus on the heart, collecting up to four times more counts than conventional, large-bore, parallel-hole collimators; cardio-centric orbit acquisition, which ensures that the heart is always in the SmartZoom collimator’s “sweet spot,” or magnification zone, as opposed to the gantry’s mechanical center; and, lastly, a proprietary 3-D reconstruction algorithm that models the position of each of the 48,000 collimator holes on each detector, allowing state-of-the-art distant-dependent isotropic (3-D) resolution recovery, CT-based attenuation correction (when using SPECT•CT), and energy window-based scatter correction.

For more information: www.siemens.com

Related Content

ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
July 7, 2017 — Blood clots in veins a
Sponsored Content | Videos | Clinical Decision Support | June 29, 2017
Rami Doukky, M.D., system chair, Division of Cardiology, professor of medicine, Cook County Health and Hospitals Syst
Dual-Agent PET/MR With Time of Flight Detects More Cancer

Tc-99m MDP bone scan (left) is negative for osseous lesions. NaF/FDG PET/MRI (right and second slide) confirms absence of bone metastases, but shows liver metastases. Image courtesy of Stanford University.

News | PET-MRI | June 20, 2017
Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (...
Combined Optical and Molecular Imaging Could Guide Breast-Conserving Surgery

WLE specimen from a patient with a grade 3, ER-/HER2-, no special type (NST) carcinoma. (A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov signal. An increased signal from the tumor is visible (white arrows); mean radiance is 871 ± 131 photons/s/cm2/sr, mean TBR is 3.22. Both surgeons measured the posterior margin (outlined in blue) as 2 mm (small arrow); a cavity shaving would have been performed if the image had been available intraoperatively. The medial margin (outlined in green) measured >5 mm by both surgeons. Pathology ink prevented assessing the lateral margin; a phosphorescent signal is visible (open arrows). (C) Specimen radiography image. The absence of one surgical clip to mark the anterior margin, and the odd position of the superior margin clip (white arrow) prevented reliable margin assessment. (D) Combined histopathology image from two adjacent pathology slides on which the posterior margin (bottom of image) and part of the primary tumor are visible (open arrows). The distance from the posterior margin measured 3 mm microscopically (double arrow). The medial margin is > 5 mm (not present in image). Credit: A. D. Purushotham, M.D., King’s College London, UK

News | Nuclear Imaging | June 20, 2017
June 20, 2017 — Breast-conserving surgery (BCS) is the primary treatment for early-stage...
Overlay Init